Antiparasitic Drugs: Malaria and Helminths

Antiparasitic drugs treat infections caused by eukaryotic parasites, spanning single-celled protozoa such as the malaria parasite Plasmodium and multicellular worms (helminths). Because parasites are eukaryotes, effective drugs exploit parasite-specific biochemistry, such as the malaria parasite's handling of heme during haemoglobin digestion, or neuromuscular targets unique to worms.

Definition

Antiparasitic drugs are agents that kill or inhibit parasitic protozoa and helminths; antimalarials act against Plasmodium species (notably during the blood stage), and anthelmintics act against parasitic worms, in both cases by targeting parasite-specific structures or pathways.

Scope

The topic introduces the two most prominent groups of antiparasitic therapy by disease burden: antimalarials directed at Plasmodium, and anthelmintics directed at intestinal and tissue worms. It describes representative mechanisms and the central problem of resistance, especially in malaria. It is educational reference and does not provide regimens, dosing, or individualized treatment advice.

Core questions

• What parasite-specific targets do antimalarials and anthelmintics exploit?
• Why has artemisinin-based combination therapy become central to malaria treatment?
• How does drug resistance threaten antimalarial efficacy?

Key concepts

• Eukaryotic parasites and the challenge of selective toxicity
• Plasmodium blood-stage targets and heme detoxification
• Artemisinins and artemisinin-based combination therapy
• Anthelmintic neuromuscular and microtubule targets
• Mass drug administration for helminth control
• Antimalarial drug resistance
• Combination therapy to delay resistance

Mechanisms

Antimalarials act mainly on the blood stage of Plasmodium, where the parasite digests host haemoglobin and must detoxify the resulting heme; several classes interfere with this process or with related parasite biochemistry, and artemisinins are activated by heme/iron to generate reactive intermediates that damage parasite molecules, producing rapid killing. Because resistance has repeatedly emerged to single agents, fast-acting artemisinins are paired with a longer-acting partner drug in artemisinin-based combination therapy, the combination being intended to clear parasites quickly and protect each component from resistance. Anthelmintics act by parasite-selective mechanisms: some classes target nematode neuromuscular signalling to paralyse worms, while benzimidazoles bind parasite tubulin and disrupt microtubule function. These mechanisms underlie both individual treatment and large-scale control programmes.

Clinical relevance

Antimalarials and anthelmintics are mainstays of global infectious-disease control, used both for individual treatment and in preventive mass drug administration for helminths. This entry explains how the drugs work and why resistance matters as background for evidence appraisal; it is not a source of dosing or treatment recommendations.

Epidemiology

Malaria remains one of the most important parasitic diseases worldwide, concentrated in tropical regions, while soil-transmitted helminth infections (ascariasis, trichuriasis, and hookworm) affect a very large share of the global population, particularly in low-income settings, making these two drug groups central to global health.

History

Antimalarial therapy evolved from quinine and the synthetic 4-aminoquinolines to artemisinin, whose discovery from traditional Chinese medicine was recognized with a Nobel Prize and which now anchors first-line combination therapy. For helminths, the introduction of broad-spectrum benzimidazoles and other anthelmintics enabled both clinical treatment and the mass drug administration campaigns central to modern control of neglected tropical diseases.

Debates

How serious is artemisinin resistance for malaria control?

Reduced parasite clearance with artemisinins, first documented in Southeast Asia, raised concern that resistance could spread and undermine artemisinin-based combination therapy, intensifying debate over containment, partner-drug choice, and surveillance.

Key figures

• Nicholas White
• Tu Youyou
• Peter Hotez

Seminal works

• white-2014
• bethony-2006
• dondorp-2009

Frequently asked questions

Why are antimalarials usually given in combinations?

Combining a fast-acting artemisinin with a longer-acting partner drug clears parasites rapidly and reduces the chance that resistance to either component will emerge, which is why artemisinin-based combination therapy is the standard approach.

Why are parasites hard targets for drugs?

Parasites are eukaryotes and share much biochemistry with their hosts, so antiparasitic drugs must exploit the relatively few parasite-specific features, such as the malaria parasite's heme handling or worm-specific neuromuscular and tubulin targets.